Cytosorbents (NASDAQ:CTSO) Issues Quarterly Earnings Results, Beats Estimates By $0.32 EPS

Cytosorbents (NASDAQ:CTSO – Get Free Report) announced its quarterly earnings results on Thursday. The medical research company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.32, Zacks reports. The business had revenue of $9.73 million for the quarter, compared to analysts’ expectations of $9.90 million. Cytosorbents had a negative net margin of 45.06% and a negative return on equity of 689.23%.

Here are the key takeaways from Cytosorbents’ conference call:

  • CytoSorbents reported third-quarter operating cash flow of about $43,000, excluding restructuring payments, meeting its stated breakeven objective. Product gross margin rose to 75% and adjusted EBITDA loss narrowed to about $284,000, though management cautioned that cash flow may fluctuate and breakeven is not guaranteed every quarter.
  • Revenue increased 3% year over year to $9.7 million, with distributor and partner sales up 18%, but sales in Germany fell about 20%–21% amid reduced sales-force coverage. The company has begun rebuilding its German team and plans further hires, while targeting sustainable product gross margins in the mid-70% range.
  • The company is preparing an expanded DrugSorb-ATR De Novo submission for ticagrelor use in early 2027, pending completion of an animal study and further regulatory work; it also expects a separate DOAC pathway submission in 2027. Management cited encouraging clinical evidence and FDA discussions, but U.S. authorization and timing remain uncertain.
  • CytoSorbents is exploring non-dilutive funding, partnerships, licensing, and other strategic options for HemoDefend-BGA, a blood-product filtration technology, aiming to unlock value without significant investment from core operations. No specific deal or funding outcome was announced.
  • The company ended the quarter with $5.7 million in cash, cash equivalents, and restricted cash, and said it is working to meet its remaining Nasdaq listing requirement and restructure its debt by year-end. Its ability to complete those efforts and finance the business remains uncertain.

Cytosorbents Stock Down 9.3%

CTSO opened at $4.87 on Friday. Cytosorbents has a fifty-two week low of $2.84 and a fifty-two week high of $17.00. The firm has a market capitalization of $15.34 million, a P/E ratio of -0.91 and a beta of 1.49. The company’s 50-day moving average is $4.88 and its 200 day moving average is $9.07. The company has a debt-to-equity ratio of 4.70, a current ratio of 0.66 and a quick ratio of 0.50.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on CTSO shares. Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a report on Friday, October 2nd. WBB Securities initiated coverage on Cytosorbents in a report on Wednesday, October 21st. They set a “speculative buy” rating and a $9.50 price target for the company. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Cytosorbents currently has an average rating of “Hold” and a consensus target price of $104.75.

Get Our Latest Analysis on CTSO

Insider Transactions at Cytosorbents

In other news, CEO Phillip Chan acquired 200,000 shares of Cytosorbents stock in a transaction on Friday, September 4th. The stock was acquired at an average cost of $0.35 per share, with a total value of $70,000.00. Following the transaction, the chief executive officer owned 1,944,432 shares of the company’s stock, valued at approximately $680,551.20. This trade represents a 11.47% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 7.80% of the company’s stock.

About Cytosorbents

(Get Free Report)

CytoSorbents Corporation is a medical device and healthcare company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent materials that can bind and remove cytokines, inflammatory mediators, drugs, and other molecules during extracorporeal blood treatment. The company’s principal product is CytoSorb, an extracorporeal cytokine adsorber used in critical care and cardiac surgery applications.

Featured Articles

Earnings History for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.